ReNeuron Raises $50M For Stem Cell Trials In Stroke, Limb Ischemia And Sight Loss
This article was originally published in The Pink Sheet Daily
Executive Summary
New and existing investors back early clinical studies by leading U.K. stem cell company ReNeuron, including potential therapies for stroke, limb ischemia, and retinitis pigmentosa, as well as other sight destroying conditions like age-related macular degeneration.